Kite Pharma +35% following non-Hodgkin's lymphoma drug study result

Kite Pharma (NASDAQ:KITE) +34.5% AH after announcing positive results in a clinical study of patients receiving Kite's treatment for non-Hodgkin's lymphoma.

The clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute found that in 12 of 13 evaluable patients with advanced B-cell malignancies receiving Kite's anti-CD19 CAR T cell therapy resulted in complete remission in eight patients and partial remission in four patients.

Based on the study, Kite says it plans to file an Investigational New Drug Application during Q4.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs